Kazia Executes Agreement To Commence GBM Agile Pivotal Study
SYDNEY, Oct. 16, 2020 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce that it has executed a definitive agreement with the Global Coalition for Adaptive Research (GCAR) to commence Kazia's participat...
Kazia Enters Clinical Collaboration With Dana-farber Cancer Institute For Primary CNS Lymphoma
SYDNEY, Sept. 22, 2020 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce that it has entered into a collaboration with Dana-Farber Cancer Institute (DFCI) inthe United States, to investigate the use of...
US FDA Awards Orphan Drug Designation (ODD) To Paxalisib For Malignant Glioma, Including DIPG
SYDNEY, Aug. 24, 2020 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce that the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to Kazia's paxalisib (formerl...
US FDA Awards Fast Track Designation (FTD) to Paxalisib for Glioblastoma
SYDNEY, Aug. 20, 2020 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce that the United States Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to Kazia's paxalisib (forme...
US FDA Grants Rare Pediatric Disease Designation (RPDD) to Paxalisib for DIPG
SYDNEY, Aug. 7, 2020 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce that the United States Food and Drug Administration (FDA) has awarded Rare Pediatric Disease Designation (RPDD) to Kazia's paxalis...
Kazia Presents Further Paxalisib and Cantrixil Data at AACR, Reinforcing Positive Efficacy Signals for both Drugs
SYDNEY, June 22, 2020 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to share poster presentations of interim data from the ongoing phase II study of paxalisib (formerly GDC-0084) in glioblastoma, the most com...
Kazia Presents Interim Paxalisib Phase II Data at ASCO Showing Positive Overall Survival Signal
SYDNEY, June 1, 2020 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to share a poster presentation of interim data from the ongoing phase II study of paxalisib (formerly GDC-0084) in glioblastoma, the most comm...
Kazia's Paxalisib Shows Positive Overall Survival Signal in Phase II Glioblastoma Study
SYDNEY, April 7, 2020 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to share positive interim data from its ongoing phase II study of paxalisib (formerly GDC-0084) in glioblastoma, the most common and most agg...
Kazia Initiates Preparatory Activities to Bring GDC-0084 into GBM AGILE, an International Phase II / III Study in Glioblastoma
SYDNEY, Dec. 11, 2019 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce that it's lead program, GDC-0084, has been selected to join GBM AGILE, an international, academic-led, multi-drug adaptive phase ...
Positive Interim Efficacy Data from GDC-0084 Phase II Study in Glioblastoma Released at SNO Conference
SYDNEY, Nov. 25, 2019 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to share with investors interim data from its ongoing phase II study of GDC-0084 in glioblastoma, the most common and most aggressive form of...
Kazia Raises A$4.0 Million to Progress R&D Programs
SYDNEY, Oct. 28, 2019 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce the completion of a placement of ten million new fully paid ordinary shares in the Company (New Shares) to institutional, profess...
Kazia wins ANZLF Trans-Tasman Innovation & Growth Award and reports new data from clinical trial in childhood brain cancer
SYDNEY, Sept. 13, 2019 /PRNewswire/ -- Australian oncology-focused biotech company Kazia Therapeutics Ltd (ASX: KZA, NASDAQ: KZIA) is pleased to announce that it has been named as a winner in the 2019 ANZLF Trans-Tasman Innovation & Growth Awards. The Awards celebrate the innovation, growth and ...
St Jude Study of GDC-0084 in DIPG Successfully Completes First Stage; Second Part of Study Now Underway
SYDNEY, Sept. 12, 2019 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce that St Jude Children's Research Hospital has successfully completed the first stage of its ongoing phase I study of Kazia's in...
Kazia to test GDC-0084 with Radiotherapy in Phase I Clinical Trial at Leading US Cancer Center
SYDNEY, July 22, 2019 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce that Memorial Sloan Kettering Cancer Center (MSK) inNew York, NY will investigate the potential use of Kazia's investigational ne...
Kazia calls for greater awareness of the deadliest brain cancer in the US
SYDNEY, July 17, 2019 /PRNewswire/ -- This Glioblastoma Awareness Day, Australian oncology-focused biotech company, Kazia Therapeutics Ltd (ASX: KZA, NASDAQ: KZIA), calls for greater awareness of the most lethal brain cancer in the US. Glioblastoma (GBM) is the most common, complex, treatment ...
Kazia Enters Clinical Collaboration for Metastatic Brain Cancer with Alliance for Clinical Trials in Oncology
SYDNEY, May 20, 2019 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce that it has entered into a collaboration with the Alliance for Clinical Trials in Oncology Foundation (Alliance), a US-based cance...
Kazia calls for greater awareness of the deadliest gynecological cancer in the US
SYDNEY, May 8, 2019 /PRNewswire/ -- This World Ovarian Cancer Day, Australian oncology-focused biotech company Kazia Therapeutics Ltd (ASX: KZA, NASDAQ: KZIA) calls for greater awareness of what is the most lethal gynaecological cancer in the US. In 2019, around 22,530 women will receive a new d...
Kazia calls for greater awareness of the most lethal women's disease in Australia
SYDNEY, May 8, 2019 /PRNewswire/ -- This World Ovarian Cancer Day, Australian oncology-focused biotech company Kazia Therapeutics Ltd (ASX: KZA, NASDAQ: KZIA) calls for greater awareness of what is the most lethal women's disease in Australia. Every year, approximately 1,600 Australian women are...
Kazia Presents Positive Cantrixil Phase I Data at AACR Conference
SYDNEY, April 1, 2019 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to provide investors with a poster presentation summarising data from Part A of the ongoing phase I study of Cantrixil (TRX-E-002-1) in ovari...
Kazia to present on Cantrixil at American Association for Cancer Research (AACR) 2019 Annual Meeting
SYDNEY, March 25, 2019 /PRNewswire/ -- Australian oncology-focused biotech company Kazia Therapeutics Ltd (ASX: KZA, NASDAQ: KZIA) has been selected to present data from the Phase I study of Cantrixil in ovarian cancer at the American Association for Cancer Research (AACR) 2019 Annual Meeting. A...
